Amy Blum

Castle Biosciences, Inc.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett's esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient's tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett's Esophagus is the world's first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett's esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.